InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial
First adolescent patient enrolled into clinical trial With the DMC approval to enroll adolescent patients into InMed's INM-755 Phase 2 clinical trial, the first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece. Patent granted in Japan: InMed has recently been granted a patent for the use of CBN in the treatment of EB in Japan. This patent allows for the use of topically administered CBN in patients with epidermolysis bullosa simplex (EBS). The Company's overall patent strategy is to
continue to prosecute patent applications in other jurisdictions including Europe and the United States. Eight clinical trial sites fully activated: InMed's Phase 2 clinical trial now has eight clinical trial sites fully activated to screen and enroll patients. Two more sites are expected to be fully activated soon. The clinical trial is taking place in seven countries including Austria, Germany, Greece, France, Italy, Israel and Spain. The planned clinical site in Serbia will not be participating in the study due to staffing capacity issues related to the ongoing impact of the COVID-19 virus.